Table 2. Clinical-phase anticancer antibodies incorporating Fc modifications.
| Ab name | Target | Technology | Clinical phase | Company |
|---|---|---|---|---|
| XmAb2513 | CD30 | XmAb Fca | Phase I | Xencor |
| MDX-1401 | CD30 | Potelligentb | Phase I | Medarex |
| BIW-8962 | Ganglioside GM2 receptor | Potelligent | Phase I/II | Kyowa Hakko Kirin (Biowa) |
| Afutuzumab | CD20 | GlycoMAbc | Phase II | Roche (Glycart) |
| R7160 | EGFR | GlycoMAb | Phase I | Roche (Glycart) |
Abbreviation: EGFR=epidermal growth factor receptor.
a
Fc protein engineering to increase Fc receptor engagement.
b
FUT8-knockout CHO cells producing non-fucosylated antibodies with increased Fc-receptor engagement.
c
Genetically engineered cells producing antibodies bearing bisected non-fucosylated oligosaccharides with increased receptor engagement.